1 What is the relationship between viral prospecting in animals and medical countermeasure

2 development?

- 3 Aishani V. Aatresh,^{1, 2*} Marc Lipsitch^{2, 3}
- ⁴ ¹Harvard College, Cambridge, MA, USA
- ² Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health,
- 6 Boston, MA, USA
- ³ Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard
- 8 T.H. Chan School of Public Health, Boston, MA, USA
- 9 *Corresponding author: <u>aishani@alumni.harvard.edu</u>
- 10

11 Abstract

- 12 In recent decades, surveillance in nonhuman animals has aimed to detect novel viruses before
- 13 they "spill over" to humans. However, the extent to which these viral prospecting efforts have
- 14 enhanced preparedness for disease outbreaks remains poorly characterized, especially in terms of
- 15 whether they are necessary, sufficient, or feasible ways to spur medical countermeasure
- 16 development. We find that several viruses which pose known threats to human health lack
- 17 approved vaccines and that known viruses discovered in human patients prior to 2000 have
- 18 caused most major 21st-century outbreaks. With *Filoviridae* as a case study, we show there is
- 19 little evidence to suggest that viral prospecting has accelerated countermeasure development or
- 20 that systematically discovering novel zoonotic viruses in animal hosts before they cause human
- 21 outbreaks has been feasible. These results suggest that prospecting for novel viral targets does
- 22 not accelerate a rate-limiting step in countermeasure development and underscore questions
- about the importance of zoonotic viral discovery for outbreak preparedness. We consider
- 24 limitations to these conclusions and alternative but related approaches to preparedness and
- 25 response.
- 26
- 27 Keywords: preparedness, surveillance, zoonoses, spillover, medical countermeasures, vaccines,
- 28 virus families, Ebola, Marburg
- 29

30 Abbreviations

- 31 CEPI: Coalition for Epidemic Preparedness Innovations
- 32 DON: Disease Outbreak News
- 33 EVD: Ebola virus disease
- 34 MCM: medical countermeasure
- 35 MVD: Marburg virus disease
- 36 NIAID: National Institute of Allergy and Infectious Diseases
- 37 PHEIC: Public Health Emergency of International Concern
- 38 UKVN: UK Vaccines Research and Development Network
- 39 USAID: United States Agency for International Development
- 40 WHO: World Health Organization

41 Introduction

42

43 In recent decades, concerns about viruses that have the potential to "spill over" from non-human 44 animals to humans and cause the next infectious disease outbreak or widespread epidemic have 45 driven systematic efforts to characterize viral diversity and discover novel viral species in animal hosts, including those that may be or become reservoirs for spillover into humans.^{1, 2, 3, 4} The 46 COVID-19 pandemic has intensified a focus on and controversies around attempts at viral 47 48 discovery as a means to isolate potentially zoonotic or currently unknown "Disease X" viruses from animals before they spill over to humans.⁵ Surveillance in animals, especially wildlife, to 49 50 this end has been a central element of One Health initiatives in renewed discussions about and global efforts toward pandemic prevention, preparedness, response and resilience.^{6, 7} However, 51 52 some elements of animal virus surveillance projects remain poorly defined, namely: how 53 knowledge of viral zoonoses in animals has contributed to outbreak preparedness and response, 54 what assumptions motivate large-scale viral surveillance in animals and whether they hold, and 55 whether the benefits claimed to be attainable through such viral discovery have proven realistic. 56 Current estimates suggest that approximately 250 viruses are known to infect humans⁸ and 57 58 implicate zoonotic spillovers as the proximate causes for approximately 60% of emerging infectious disease events, with wildlife origins for about 70% of these spillovers.^{9, 10} Examples of 59 60 such emerging infectious disease events — defined as the first occurrence of a pathogen in a human population, an increase in the geographic range or incidence of a previously known 61

62 pathogen, or a major change in pathological or clinical presentation — range from Crimean-

63 Congo hemorrhagic fever (CCHF) and Nipah virus infection to yellow fever and Ebola virus

64 disease. Remaining diseases have emerged or were caused by other types of pathogenic agents

65 (e.g., bacteria or fungi), human-to-human transmission of a virus, or a pathogen of unknown

origin. One study posits that over 600,000 unknown viruses with the potential to infect humans
 lurk in birds and non-human mammals,¹¹ while another more recent estimate suggests that

lurk in birds and non-human mammals,¹¹ while another more recent estimate suggests th
 10,000 viruses with zoonotic potential circulate in non-human mammals.¹²

69

70 The extent of unknown viral diversity and possible opportunities to better understand viral

71 ecology and disease emergence have been invoked to champion discovering viruses in animal

hosts before human outbreaks as a means to improve global preparedness for such outbreaks.

- 73 PREDICT is one notable example of a viral discovery program with a focus on systematically
- sampling animals for viruses of future relevance. It was led by the United States Agency for
- 75 International Development (USAID) and University of California at Davis from 2009 through
- 76 2020 with partnerships in over 30 countries. This project focused on "[p]redicting where new

diseases may emerge from wild animals, and detecting other pathogens before they spread

among people [to] give us the best chance to prevent new pandemics"¹³ by advancing an

79 "approach in which pathogens of pandemic potential are discovered at their source before large-80 scale epidemics occur in people."¹ We term these systematic predictive efforts for "finding

81 viruses in wildlife before they emerge in humans¹⁴ viral prospecting to distinguish discovering

82 and forecasting future disease threats from capacity-building for surveillance of known viruses,

83 another major aim of PREDICT-style programs.

84

85 To date, assessments of animal viral discovery efforts primarily have focused on the distribution

of and disease burden in host and reservoir species,^{4, 15} sampling and viral discovery curves, ^{16, 17},

¹⁸ cost-benefit analyses,¹⁹ and predictive methods to compute the likelihood of spillover across
 viral species given various variables of interest.^{20, 21} Efforts to rank which known viruses are

89 most likely to spill over from animals to humans have incorporated novel sequences from such

- 90 efforts with expert predictions and ecological data. One such study suggests that the top 12 are
- 91 zoonotic viruses that have already been well-characterized, while half of the remaining top 50
- 92 were various coronaviruses sampled primarily from bats. Notably, this study used observed
- 93 spillover as one of its predictors, risking circularity.²²
- 94

95 Critiques of virus prospecting have revolved around safety risks and, to a lesser extent, whether

96 the viruses discovered are of significant value for human health. Some reports in the literature 97 document wildlife biologists bitten by host species known to harbor viral zoonoses during field

document wildlife biologists bitten by host species known to harbor viral zoonoses during field
 sampling efforts, with infection in some cases.^{23, 24} With more recent controversies around the

origins of the COVID-19 pandemic, biosafety has also been raised as reason to terminate large-

100 scale prospecting projects. $^{25, 26, 27}$ Other commentaries focus on mechanisms to mitigate zoonotic

- 101 spillover^{7,28} or concerns about the feasibility of prospecting efforts and its consequences of
- 102 unmet expectations for trust in science.²⁹ For instance, PREDICT detected over 800 novel
- 103 viruses, some of which were novel strains of known viruses based on a pairwise sequence
- 104 identity cut-off, in samples from approximately 7,000 animals tested across 15 taxonomic

105 families with known viruses that infect humans.²² However, project meta-analyses note that out

106 of the total effort — more than 500,000 samples primarily from over 70,000 animals — just one

107 of these novel viral species is known to be capable of causing disease in humans, and it was only $\frac{100}{200}$

108 discovered while research teams were supporting the investigation of an outbreak in humans.^{30, 31} 109

110 The promises of viral prospecting efforts like PREDICT extend beyond advances in basic

science and knowledge of ecological diversity or international development. Some researchers have argued that viral prospecting holds direct benefits for predicting disease emergence and

113 accelerating medical countermeasure (MCM) development for those future diseases.^{32, 33, 34, 35, 36,}

^{37, 38} Having vaccines at-the-ready during an emerging outbreak has become an increasingly central focus in disease preparedness discussions and predictive efforts over the past two

decades, with the goal that such development of medical countermeasures prior to possible large-

scale human outbreaks will reduce their morbidity, mortality, and economic consequences.^{39, 40},

⁴¹ The literature to date pays comparatively less attention to evidence for these potential

119 translational impacts of viral discovery. Nonetheless, next-generation viral prospecting projects

120 call for over one billion dollars in funding and "envisage countries working together to fund viral

121 discovery programs that upload sequence data in almost real-time, so that it can be used to

identify those microbes most likely to be able to cause zoonoses, and the data then can be used to
 block spillover and create vaccines."⁴²

124

Put differently, rationales for surveillance projects to predict future outbreaks advance and are supported by the potential for specific follow-on interventions and benefits from them. These include building technical capacity in areas of high spillover potential or reducing contact at human-wildlife interfaces to contain viruses — for example, by measures that restrict live animal sales or hunting reservoir species. However, this Analysis approaches viral prospecting in terms of aforementioned MCM development-related rationales, which is one of the most tangible and

131 widely discussed objectives for 21st-century preparedness efforts. We assess to what extent viral

132 prospecting especially in wildlife has enabled accelerated medical countermeasure development

- 133 to strengthen preparedness and response for past outbreaks in humans. Where other studies have
- aimed to weigh tradeoffs and risks or costs and benefits of animal surveillance, we focus on first
- 135 understanding these possible benefits: what would need to be true for them to be realized as
- 136 suggested, and to what extent have foundational assumptions and projections about them
- 137 materialized over time?
- 138
- 139 In light of calls for intensified animal surveillance to predict and prepare for future epidemics,
- 140 we attempt to address these questions by testing two primary hypotheses: that viral surveillance
- 141 in animals identifies potential (pre-emptive) and actual (post-hoc) causes of outbreaks in
- 142 humans, and that it translates to accelerated MCM development. We identify and assess a series
- 143 of related conditions that would need to hold true to justify arguments for the necessity,
- sufficiency, and feasibility of animal viral prospecting: (i) past efforts at viral prospecting have
- 145 paid off in that scientists have first discovered in zoonotic hosts viruses which do later cause
- 146 disease in humans; (ii) the discovery of a virus in an animal host prior to the first outbreak in
- 147 humans has translated to enhanced preparedness and response capabilities, defined primarily
- 148 through available MCMs; (iii) novel viruses are causing outbreaks and plausibly could have been
- 149 discovered in an animal host prior to these outbreaks; (iv) viruses prioritized for MCM
- 150 development were discovered in animal hosts; and (v) viral prospecting supplies needed
- 151 candidates for MCM development because efforts to deal with all or most viral threats are
- underway and succeeding. We evaluate these hypotheses and assumptions through a series of
- 153 case studies across virus families, and we consider limitations of these analyses alongside
- 154 possible alternative approaches.

155 Results

156

Discovery of a virus prior to its first documented outbreaks in humans has limited bearing on preparedness and response

159

160 We first evaluated which viruses known to cause disease in humans were first discovered in 161 animals and whether their discovery in an animal host or vector has had a substantial bearing on 162 preparedness and response. In assessing how each of the approximately 250 viruses known to 163 infect humans was first isolated, we identified eleven viruses that were isolated in animals prior 164 to causing eventual clusters of cases in humans (Table 1). With the exception of monkeypox and 165 Puumala viruses, all of these viruses are transmitted by mosquitoes and cause vector-borne 166 diseases. Three — monkeypox, Rift Valley Fever, and Zika — have caused several notable 167 outbreaks of disease in humans in the decades since their discovery. Knowledge of these viruses 168 from an animal source prior to their first outbreaks in humans has not translated to a distinctively robust capacity to prevent or respond to future outbreaks; each has spread beyond previously 169 contained regions.^{43, 44, 45} Furthermore, there is no licensed vaccine against Zika or Rift Valley 170 Fever for use in humans, while those approved for monkeypox virus are at the time of writing all 171 repurposed or expanded-use smallpox vaccines.⁴⁶ The other viruses on this list cause seemingly 172 173 limited disease in humans as detected through often-scant diagnostic and surveillance capacity.

174

Virus	Discovered	1 st documented human outbreak	Conditions of isolation and description
Barmah Forest	1989	1992	Culex mosquitoes in Australia
Bunyamwera	1943	1955	Through yellow fever surveillance in Uganda
Eastern equine encephalitis	1831	1938	North American horses
Monkeypox	1958	1970	Research monkeys; first observed human infection in child in DRC. Zoonotic reservoir unknown.
Ngari	1979	1993	Aedes simpsoni mosquitoes in Senegal
Puumala	1979	2000	Bank voles in Finland
Rift Valley Fever	1931	1975	Outbreak on a sheep farm in Kenya
Semliki Forest	1942	1987	Aedes abnormalis mosquitoes in western Uganda
Sindbis	1952	1961	<i>Culex</i> mosquitoes in the Nile River Delta, Egypt; used as a model alphavirus in USA
Venezuelan equine encephalitis	1938	1950	From the brain of a deceased horse
Zika	1947	1952	Through yellow fever surveillance in infected rhesus macaques for research use

175 Table 1: Viruses first discovered in animals before causing an outbreak in humans

176


177 21st century outbreaks of international concern largely have been caused by known viruses 178 first discovered in humans

179

We next assessed whether other previously novel viruses, which might have plausibly been discovered in animals, are causing high-consequence outbreaks in humans. Data from the World Health Organization's (WHO) Disease Outbreak News system (DON) and Public Health Emergency of International Concern (PHEIC) declarations both suggest otherwise. Since 1996,

- 184 DON has function as the WHO's public online system to compile and disseminate disease event
- reports from countries and partner organizations. We subset Carlson et al.'s 1996-2019 DON
- 186 database ⁴⁷ for viral disease events to analyze where and which viruses are causing outbreaks.
- 187 We find that while certain regions dominate DON reports, a limited number of known viruses are
- causing the majority of internationally reported disease events worldwide (Figure 1). Across
 regions, the plurality of DONs are concentrated around Ebola virus, Influenza A, MERS-CoV,
- and Yellow fever. This distribution largely reflects extended and widespread outbreaks of known
- 191 viruses (e.g., Ebola) or spikes in endemic disease (e.g., Yellow fever), while fewer DONs report
- 192 instances in which spillover of a novel virus (e.g., initial emergence of MERS-CoV, Nipah virus)
- 193 drives disease.
- 194

195 Figure 1: Geographic and viral distribution of WHO DON reports (1996-2019)



Proportion of region's viral DON reports (January 1996-December 2019)

196 DON mirrors countries' infectious disease concerns, but reports primarily offer weekly updates

- and early warning signals during an emerging outbreak rather than definitive markers of
- 198 escalating disease emergencies. PHEIC declarations, on the other hand, reflect assessments that a
- 199 disease event poses a severe global threat.⁴⁸ The WHO has declared 7 PHEICs since the
- instrument was established under the 2005 revision to the International Health Regulations,
 following the 2002-2004 SARS epidemic (Table 2). PHEICs primarily have been associated with
- following the 2002-2004 SARS epidemic (Table 2). PHEICs primarily have been associated with viruses that were well-characterized or that had caused outbreaks in humans prior to the disease
- 203 event in question. In the two events (H1N1 and COVID-19) of a novel viral strain or species
- 204 leading to a PHEIC, the pathogen nonetheless belonged to an extensively studied virus family.
- 205 These data suggest that spillovers of novel zoonotic pathogens are not driving outbreaks that
- 206 countries report to the WHO or that international public health experts deem most emergent.

207

208 Table 2: WHO PHEIC declarations by viral disease and discovery status

Year	Viral Disease	Novel Pathogen?
2009	H1N1	TRUE
2014	Ebola	
2014	Polio (<i>ongoing</i> PHEIC)	
2016	Zika	
2018	Ebola	
2020	COVID-19	TRUE
2022	Mpox	

209 210

211

Viral prospecting makes limited contributions to MCM development pipelines

212 The analyses described in the preceding sections characterized what viruses are causing disease

in humans and the relationship they have to viruses discovered in animal hosts over time. We

214 next sought to address whether viral discovery in animal hosts addresses a rate-limiting step in

215 overall MCM development efforts, with a specific focus on vaccines as primary instruments for

216 preventing infection and the severity or spread of disease. Specifically, we aimed to determine if

217 viral prospecting has discovered pathogens of interest for global efforts to develop MCMs

against epidemic threats and whether scientists lack pathogens worth targeting to these ends,

such that viral prospecting might be necessary to expand vaccine development horizons.

220

221 Since 2018, comprehensive priority lists for MCM development have been released by four

222 institutions: the Coalition for Epidemic Preparedness Innovations (CEPI),⁴⁹ U.S. National

223 Institute of Allergy and Infectious Diseases (NIAID),⁵⁰ U.K. Vaccine Network (UKVN),⁵¹ and


WHO.⁵² We find that viruses prioritized for MCM development by at least one of these agencies 225

were predominantly first isolated well before 2000 and during the first documented outbreak of each virus in humans (Figure 2). Systematic viral prospecting efforts from the 21st century have

not contributed any novel zoonotic viruses to these lists, and surveillance in animals more

broadly has played a limited role in isolating priority viruses.

229



230 Figure 2: Characteristics of viral pathogens on priority lists for MCM research and development

231 Next, we characterized the state of vaccine development against known viral threats. Many 232 vaccine development efforts in the wake of COVID-19 and other recent epidemics have been schematized taxonomically by virus family, of which by some classifications there are 26 with at 233 least one virus known to infect humans.⁵³ We find that the first virus isolated in the majority of 234 these families was discovered in humans between 1940 and 1980 (Table 3). At present, a 235 236 regulatory body has approved at least one vaccine for use in humans against at least one virus in 16 of these families. Prior to 2020, this number was 14. The first vaccine approved for a 237 238 coronavirus was against SARS-CoV-2 during the COVID-19 pandemic, even though this 239 vaccine relied on years of research and development efforts against SARS-CoV and MERS-CoV 240 following human outbreaks of these two coronaviruses. The first vaccine for a pneumovirus was 241 approved in 2023 and targets respiratory syncytial virus (RSV). Of the 10 known families for 242 which no vaccine is currently approved for any virus in each family, there are some striking 243 absences. The lack of a human vaccine for any retrovirus or bunyavirus is notable, for example; 244 HIV is a prominent retrovirus that has afflicted humans for decades, and Rift Valley Fever, 245 Crimean-Congo hemorrhagic fever, and hantaviruses are long-standing disease threats from the 246 bunyavirus family. In summary, significant gaps remain in vaccine development against known 247 targets, many of which like HIV have been the focus of widespread efforts and posed significant 248 technical challenges. Zoonotic viruses discovered in animal hosts have contributed few 249 previously unknown targets of interest to further direct these efforts.

250	Table 3: Vaccine development and viral discovery across virus families						
	Family	Year 1 st vaccine approved for human use	Year 1 st virus in family isolated, source	Notes	Examples of notable viruses		
	Adenoviridae	1971	1953, human	Only vaccine against an adenovirus approved for use in US military; separate from adenoviruses used as vectors for vaccines against other pathogens			
	Anelloviridae		1997, human	Estimated >90% prevalence in population, primarily nonpathogenic			
	Arenaviridae	2006	1933, human	2006 Junin virus vaccine, only licensed for use in Argentina	Lassa fever		
	Astroviridae		1975, human				
	Bornaviridae		1975, animal	Horses and sheep extensively vaccinated			
	Bunyavirales		1931, animal	Veterinary vaccine used extensively in Africa for Rift Valley Fever (RVF)	RVF, CCHF, Hantavirus		
	Caliciviridae		1972, human	Cats vaccinated; no human concerns beyond norovirus			
	Coronaviridae	2020	1965, human		SARS-CoV-2, SARS-CoV-, MERS-CoV		
	Filoviridae	2019	1967, human		Ebola, Marburg		
	Flaviviridae	1937	1927, human		Dengue, Zika, Japanese encephalitis, Yellow fever		
	Hepadnaviridae	1981	1965, human		Hep B		
	Hepeviridae	2011	1990, human	Vaccine licensed only in China	Hep E		
	Herpesviridae		1919, human				
	Orthomyxoviridae	1945	1933, human		Influenza		
	Papillomaviridae	2006	1979, human		HPV		
	Paramyxoviridae	1963	1934, human		Measles, mumps, Nipah		
	Parvoviridae		1960, animal	Some disease in humans but usually asymptomatic; human trials stopped for severe adverse events. Family established 1975. Human disease first observed 1974.			
	Picobirnaviridae		1988, human	Opportunistic enteric pathogens			
	Picornaviridae	1955	1898, animal		Polio		

Pneumoviridae	2023	1956, animal	Separated from Paramyxoviridae, 2016	RSV
Polyomaviridae		1953, animal		
Poxviridae	1796		Edward Jenner and cowpox- based vaccination for smallpox	Smallpox, monkeypox
Reoviridae	1998	1953, human		Rotavirus
Retroviridae		1908, animal		HIV
Rhabdoviridae	1885		Louis Pasteur and inactivated rabies virus vaccine	Rabies
Togaviridae	1969	1930, animal	Separated from <i>Flaviviridae</i> , 1984	Rubella

Viral discovery in animals plays a limited role in MCM development and outbreak response for filoviruses that infect humans

254

255 Finally, we aimed to further specify relationships between animal viral discovery and MCM 256 development through a case study of the *Filoviridae* family. Two of its genera, *Ebolavirus* and 257 Marburgvirus, include zoonotic viral species that have caused several outbreaks in humans over 258 the past 50 years. The 2013-2016 Ebola epidemic in West Africa is the largest filovirus outbreak to date, with over 28,000 cases and 11,000 deaths.⁵⁴ Since the first international reports of 259 disease several decades ago, extensive resources have been devoted to detecting filoviruses in 260 261 animals. Outbreaks of both Ebola virus disease (EVD) and Marburg virus disease (MVD) in 262 2022 and 2023 notably occurred in countries across sub-Saharan Africa where cases had not 263 been previously documented, underscoring increasing international concern about filoviruses.

264

265 The first filovirus cases in humans were documented in 1967 during two simultaneous Marburg

virus outbreaks in Germany and then-Yugoslavia, both of which were traced back to infected

laboratory African green monkeys (Figure 3A). The next several Marburg cases were

268 predominantly reported in tourists who had visited caves that were known bat habitats in various

269 African countries' national parks, with occasional reports of disease in miners. Other outbreak

investigations have found either tenuous or no epidemiological or genomic links to bats, in cavesor elsewhere, as a putative source of infection (Supplementary Information). The largest MVD

or elsewhere, as a putative source of infection (Supplementary Information). The largest MVD
 outbreak to date began in Angola in 2004, infecting over 250 people and causing more than 225

273 deaths. It was preceded by an outbreak in 1998 in the Democratic Republic of the Congo (DRC),

now the second-largest Marburg outbreak, during which epidemiological investigations revealed

several possible years of internationally unreported MVD.⁵⁵ As early as 1987, local doctors and

two hospitals had been treating patients with "a disease called 'syndrome hémorragique de
Durba,' which was always associated with mining, was common knowledge among villagers and

health care workers in the area" and caused several outbreaks of more than 50 individuals

- 279 documented only in local records.
- 280

In 2007, animal surveillance definitively established Egyptian fruit bats as a reservoir host for
 Marburg by isolating live virus from several animals (Figure 3B). This discovery was preceded

by 16 samples from bats in caves from the DRC and Gabon that were positive for Marburg by

- 284 polymerase chain reaction (PCR) and contemporaneous with 40 samples PCR positive for a
- 285 *Marburgvirus* obtained from August 2008 through December 2009. These discoveries have been

followed since by a limited number of samples positive for any *Marburgvirus* that causes disease

in humans. Despite decades of outbreaks in humans and extensive animal surveillance efforts,

including unsuccessful attempts prior to the early 2000s, there is no approved vaccine or

therapeutic that specifically targets MVD, and no MCM has progressed past Phase I trials


(Figure 3C). Concerted pre-clinical and clinical-stage MCM development followed the 2004-

2005 Angola outbreak, with a plurality of DNA and viral vector vaccine candidates designed
 specifically using viral isolates from infections during this outbreak (Supplementary

293 Information). Research for vaccine and drug candidates has progressed during and after

subsequent human outbreaks and without any distinctive relationship to viral discovery in animal

hosts, even upon the discovery of a novel strain of Marburg virus through PREDICT.



296 Figure 3: Marburg outbreaks, animal surveillance, and MCM development

297 EVD outbreaks, animal surveillance, and MCM development present similar patterns. MCM 298 development primarily has followed the historic 2013-2016 West Africa epidemic, and animal 299 surveillance has found limited success detecting any *Ebolavirus* in samples (Figure 4). The Zaire 300 species has caused a plurality of EVD outbreaks since the first documented cases in 1976 (Figure 301 4A). Several investigations to discern outbreak origins have offered inconclusive evidence as to 302 the source of disease or implicated flare-ups of undetected human-to-human transmission. In two 303 recent notable instances of 2021 outbreaks in Guinea and the Democratic Republic of the Congo, 304 epidemiological investigations traced the outbreaks to persistent viral infections and traced non-305 spillover-related transmission chains, calling into question the degree to which zoonotic spillover 306 drives EVD outbreaks (Supplementary Information). Another study of the historic 2013-2016 307 epidemic raises questions about the hypothesis that the outbreak originated through a spillover 308 event from a bat to a child near a hollow tree in the Guinean village of Meliandou, especially with no viral genomic material recovered near this site.⁵⁶ Extended interviews with villagers 309 310 have suggested instead that a persistently infected survivor from Sierra Leone in close contact

311 with the child and his family may have first transmitted the virus.⁵⁷

312

313 Simultaneously, animal viral discovery has done little to prospectively identify novel sources of

spillover for EVD. In 2016, PREDICT detected a novel species of *Ebolavirus*, which was named

the Bombali virus and per one preliminary study could mediate entry into human cells (Figure 120, 58 H

4B).⁵⁸ However, more recent *in vivo* and *in vitro* studies suggest that *Bombali ebolavirus* has low pathogenic potential in humans, and it has not caused a documented outbreak in humans.^{59, 60}

317 pathogenic potential in numaris, and it has not caused a documented outbreak in numaris. 318 Reston ebolavirus is not known to cause disease in humans but has been detected more

frequently than any other *Ebolavirus*, often in diseased non-human primates in laboratory

320 settings. No viral prospecting efforts have successfully isolated live virus from any putative

321 reservoir species. *Taï forest ebolavirus* was discovered when a researcher was infected during an

investigation of disease in chimpanzees, likely while conducting a necropsy, but has not caused

323 any documented outbreaks since (Supplementary Information). Furthermore, no Bombali-


324 specific MCM development has progressed to a pre-clinical phase, and no MCM has specific

325 regulatory approval for use against Sudan ebolavirus (Figure 4C). MCM development against

326 *Ebolavirus* largely has followed the 2013-2016 epidemic and focused on Zaire ebolavirus, such

that no approved MCMs were available to aid in responses for recent resurgences of *Sudan*

328 ebolavirus.



329 Figure 4: Ebola outbreaks, animal surveillance, and MCM development

330 Discussion

331

This Analysis finds that viral prospecting and animal surveillance writ large have played a
 limited role in advancing preparedness and response for viral infectious diseases in humans as

evaluated primarily through MCM development. These patterns suggest that viral prospecting

does not address a rate-limiting step for preparedness efforts, especially when considered in

336 conjunction with vast estimates of viral diversity and few parameters to guide high-yield

337 searches for viruses of consequence for human disease. Our findings raise questions about

338 whether viral prospecting is feasible, necessary, or sufficient as a means of predicting disease

339 emergence and driving MCM development for emerging infectious diseases.

340

341 On feasibility, we note that searches for viruses in animals generally have been inadequate for

342 pre-emptive and, to a lesser extent, post-hoc identification of viral threats to humans. Prospecting

343 efforts in animals to date have had limited success in identifying novel viruses likely to pose

344 substantial threats of outbreaks in humans. Efforts to definitively establish animal reservoirs for

known human pathogens have had notable failures so far, most notably for ebolaviruses. Animal

346 surveillance has achieved limited success in isolating from wildlife, especially bats, PCR or

347 antigen-positive samples of viruses that cause disease in humans. It has only isolated one novel

348 Ebola or Marburg species (Bombali ebolavirus), which seems as-yet unable to cause outbreaks in

humans — as with other novel filoviruses discovered through viral prospecting $^{61, 62}$ — and has

- 350 received scant attention as a target for MCM development.^{63, 64}
- 351

On sufficiency, we find for the 11 viruses to our knowledge discovered in a zoonotic host before causing documented clusters of cases in humans that there have been few differences in capacity

for preparedness and response relative to other threats first discovered during a human outbreak,

as well as no identifiable advances in preparedness between discovery in an animal and

356 subsequent human outbreaks. Most of these viruses do not (yet) cause notable outbreaks in

humans. Three viruses have caused several significant outbreaks, and MCM development against

these three has not progressed differently from viral threats discovered in other ways. We note

that while mosquito-based surveillance, especially for yellow fever, has identified several viruses with the ability to cause disease in humans and enabled various ecological and virological studies

361 during and prior to outbreaks, systematic animal surveillance efforts in wildlife or domestic

animals — the focus of most viral prospecting efforts today — have found comparatively limited
 success.

363 364

365 On necessity, there are still no vaccines approved for use in humans against any virus in 10 of 26 366 virus families with at least one virus known to infect humans, and the majority of disease 367 outbreaks in humans involve known human pathogens or close relatives of known human 368 pathogens. Even within the 16 of 26 virus families that contain at least one virus with an 369 approved vaccine, several known threats (e.g., Zika, West Nile, Nipah, Lassa) with demand for a 370 vaccine do not have a countermeasure approved for widespread use. This undermines the 371 hypothesis that a lack of candidate pathogens known prior to outbreaks is a limiting factor in our 372 ability to develop MCMs and advance preparedness. On the contrary, most priority viruses for 373 current MCM development efforts are pathogens that were discovered several decades ago but remain "high-value" targets with a lack of effective interventions, for reasons ranging from 374

375 technical challenges to market failures.⁶⁵ Larger regional outbreaks have instead been the

- 376 catalyzing force for accelerated R&D, especially with vaccines. These data do not account for
- arly-stage research for vaccine candidates often funded by various national funding agencies.
- 378 However, they reflect the degree to which R&D efforts have not exhausted the work required to
- translate from known viral threats to approved vaccines against them.
- 380

381 Our analyses of filoviruses point at a larger body of research regarding viruses with known 382 zoonotic hosts or assumed reservoirs that sometimes reemerge due to undetected or new modes of human-to-human transmission rather than new spillovers.^{66, 67, 68, 69, 70, 71, 72, 73} This raises 383 questions about the degree to which outbreak frequency is increasing relative to public health 384 385 capacity to detect outbreaks and coordination between local health efforts or institutions and 386 international public health bodies. The case for being able to prospectively identify the source of 387 a possible future outbreak from an animal reservoir to advance preparedness is relatedly tenuous, 388 in light of notable difficulties associated with retrospectively discerning the origins of known 389 outbreaks. Surveillance in animals with the goal of finding viruses with a high risk for spillover 390 presumes that we have valid and reliable predictors of what viruses are likely to spill over and 391 from where. The fact that we often cannot definitively isolate the putative virological source of 392 an outbreak suggests that we do not have the data to generate such an account. Repeated 393 spillovers of known viruses and flare-ups of human transmission that was previously undetected 394 each contribute to the burden of disease emergence in a way that viral prospecting cannot 395 significantly address. The filoviruses case study and our analyses more broadly instead suggest 396 that existing disease in humans offers the best frameworks for preparedness and proxy for future

- 397 disease widespread events in humans.
- 398

399 These analyses have some limitations, including a exclusive focus on viral pathogens (not 400 bacterial or other zoonoses). First, filoviruses present one possible "best-case" scenario for MCM 401 development, given extensive attention as a biosecurity concern. They do not pose the same 402 challenges of respiratory transmission and high mutation rates that might more strongly motivate 403 discovery efforts for coronaviruses or orthomyxoviruses (influenza). Second, our analysis mainly 404 addresses a very specific endpoint of regulatory approval or lack thereof for the use of a vaccine 405 in human populations, but it neither evaluates general capacity for scaled-up, widespread MCM 406 manufacturing and equitable access nor accounts for veterinary vaccine development. Third, we 407 do not make any explicit cost-benefit or risk-reward assessments. Finally, this analysis considers 408 neither capacity-building and behavioral interventions nor research characterizing mechanisms 409 such as viral entry or replication as a result of viral prospecting. We also note that the 410 characterization of viral diversity and detection of viral threats are two distinct goals implicated 411 in virus prospecting projects, and our study focuses on the latter. It relatedly does not account for 412 less tangible ways in which prior knowledge about viruses, general healthcare system 413 strengthening, or non-pharmaceutical interventions have factored into outbreak responses but 414 does not equate the lack of direct MCM development with a lack of value for virus prospecting. 415 416 However, one possible implication of our analysis is that capacity-building through other 417 activities such as (i) the surveillance of endemic viruses or disease in humans, rather than 418 animals, and (ii) the prevention of ongoing spillover of known viruses, such as Nipah, by 419 measures to reduce human contact with reservoirs and materials they contaminate.⁷⁴ might still 420 advance similar characterization-style goals of basic research. Such an approach may also

421 contribute more concretely and reliably to preparedness efforts against future known and

422 unknown threats, whether through vaccine development projects or other such initiatives that423 require dedicated technical, political, and financial resources.

424

425 We additionally evaluate two major plausible responses to our data and conclusions. The first is 426 that these results only underscore the need for more extensive viral prospecting and MCM 427 development efforts by highlighting the shortcomings of limited resources and efforts thus far. 428 We note, however, the demonstrated difficulty of robustly assessing the pathogenicity of all 429 viruses discovered through such initiatives and the various bottlenecks associated with 430 translating knowledge of a virus to a usable vaccine or therapeutic. Scaling viral prospecting 431 would not address these translational gaps, which themselves suggest that technical deficits in 432 preparedness lie more in R&D or health-related infrastructure rather than predictions about 433 viruses to target. A second response is that increased animal surveillance would allow more work 434 to manage and curb human-wildlife interactions to stop possible spillover events before they even occur, especially in developing countries and through practices such as bushmeat hunting.⁷⁵ 435 However, the realities of an unequal and globalized world complicate this focus as a simple or 436 437 all-encompassing policy intervention. For example, bats are a source of subsistence food and income in some rural communities in Africa,⁷⁶ while several internationally driven development 438 439 projects have disrupted ecosystem dynamics in ways that have brought humans and animals closer together and exacerbated disease risk.⁷⁷ On the other hand, intensive agricultural 440 441 practices¹⁰ or various factory farming-related risks of spillover from animal hosts for countries 442 like the United States have gone somewhat unattended, such that responses to recent zoonotic 443 outbreaks such as H5N1 from cattle have suffered from a lack of coordinated infrastructure. To 444 address risks of spillover, then, would involve addressing social and economic dimensions of the 445 contexts in which disease emerges. On their own, efforts to discover novel viruses pre-emptively 446 offer little by way of predicting the ways in which people will respond to disease threats or deem

447 preparedness measures adequate, suggesting that prediction as a paradigm itself requires

- refinement to offer legitimate predictive "power" for future problems.⁷⁸
- 449

450 Further analyses of animal surveillance and viral prospecting might develop case studies across

different virus families to specify the conditions under which such efforts would be most

452 beneficial or track publications over time directly linked to linked to discoveries from viral

453 prospecting. Additional work might chart MCM development timelines across clinical trials and

454 MCM type across and within each virus family or characterize sampling efforts by assessing

455 genomic diversity of sequences from animal surveillance relative to known human infections.456

457 In terms of interventions for preparedness and response such as surveillance and R&D, history 458 suggests that prospecting for novel viruses is unlikely to find the next Disease X before it "finds 459 us." We suggest that public health and policy decision-makers consider what specific forms of 460 information and coordination allow for more targeted efforts that matter to people's lives in the 461 face of infectious disease threats instead of merely populating a universalizable database of viral 462 zoonoses. As others have proposed, more focused serological and viral surveillance for disease 463 in humans who are in contact with wildlife or livestock might provide more effective proxies for 464 emerging disease risks and a clearer picture of disease burden while furthering knowledge of viral ecology.^{29, 79} Organizations like CEPI were created to address gaps in R&D efforts, 465 especially in relation to market failures. Further efforts to advance clinical trials during 466

467 outbreaks, including through innovative trial design and use of correlates of protections, and to

develop MCMs that can be stockpiled prior to an outbreak would work to close gaps for knownthreats in ways that would build a stronger foundation for responses to yet-unknown viruses.

470

471 The lack of promised benefits from animal surveillance, alongside the extensive costs and

- 472 possible risks referenced in the Introduction, point in favor of an argument for focusing resources
- 473 elsewhere. These alternative directions offer other ways to expand capacity and further basic
- 474 science whether by improving MCM development efforts for known but under-characterized
- 475 endemic threats of increasing epidemic concern, or strengthening local healthcare infrastructure
- to better ascertain and address the burden of diseases like Ebola and Marburg. Concerted
- attention to repeated and ongoing outbreaks in humans, especially in low and middle-income
- 478 countries, would serve human health writ large and bolster preparedness for future global
 479 outbreaks in the event of increased spread. Mpox, the disease associated with monkeypox virus,
- 480 offers an example of why such an approach merits further consideration. First, decades of
- 481 increased disease incidence in parts of Africa went ignored internationally until a widespread
- 482 global epidemic and PHEIC in 2022.⁸⁰ Second, one recent study suggests that what was once
- thought to be spillover-induced spread of disease was in fact undetected human-to-human
- 484 transmission.⁸¹ Third, in keeping with considerations around equity, as of April 2024 populations
- 485 affected in Africa are yet to receive a dose of the smallpox-monkeypox vaccine.⁸² The fact that
- 486 scientists discovered monkeypox in an animal prior to the first documented outbreak of the
- 487 disease in humans has had little bearing on these challenges today.
- 488

489 In summary, viral prospecting in nonhuman animals does little to detect disease threats of

- 490 consequence for human populations and has little to show in terms of advancing translational
- 491 research for MCMs. Notwithstanding the value of acquiring further knowledge about viral
- 492 diversity and expanding scientific capacity, narrow demonstrated benefits raise questions about
- 493 whether other modes of preparedness might offer more suitable ways of achieving similar and
- 494 further ends, without additional and inherent tradeoffs in cost, safety, or other domains. Closer
- 495 attention to viral diseases in humans, whether emergent or known and often under-addressed,
- 496 might instead lend itself to addressing inequalities and baseline capacity related to routine health 497 needs across the world in ways that simultaneously strengthen preparedness and response against
- 497 needs across the world in ways that s498 future emerging outbreaks.
 - 499

500 Legends

501

502 *Table 1: Viruses first discovered in animals before causing an outbreak in humans*

503

504 *Figure 1: Geographic and viral distribution of WHO DON reports (1996-2019)*

505 Regional distribution for virus-only subset of WHO Disease Outbreak News reports from

506 Carlson et al. (2023) database.

507

508 Table 2: WHO PHEIC declarations by viral disease and discovery status

509
510 Figure 2: Characteristics of viruses on priority lists for MCM research and development

511 Priority pathogens for research under WHO, NIAID (Category A), UKVN, and/or CEPI were

512 assessed for mode of transmission, first recorded outbreak, and circumstances under which they 513 were first isolated.

514

515 Table 3: Vaccine development and viral discovery across virus families

516

517 Figure 3: Marburg outbreaks, animal surveillance, and MCM development

518 A) Timeline of MVD outbreaks by country, assessment of novel spillover event as source of

519 outbreak, and primary outbreak population. The Angola outbreak, the largest recorded, is the

520 large "X" at 2004 and Africa (Central). B) Timeline of when and where samples from animals

521 were positive for Marburg virus by polymerase chain reaction. C) Timeline of published pre-

522 clinical (and non-murine) work and clinical trials by type of medical countermeasure specifically

523 targeting Marburg virus.

524

525 Figure 4: Ebola outbreaks, animal surveillance, and MCM

526 A) Timeline of EVD outbreaks by species, assessment of novel spillover event as source of

527 outbreak, and location. B) Timeline of when and where samples from animals were positive for

528 an *Ebolavirus* by polymerase chain reaction or antigen test. C) Timeline of clinical trials by type

529 of medical countermeasure specifically targeting an *Ebolavirus*.

530 **Methods**

531

532 To broadly assess relationships between discovery in animals, disease outbreaks in humans, and 533 preparedness through medical countermeasures across viral taxa, we began by referencing the

ViralZone project⁸³ (managed by the virus program of the Swiss-Prot group of the SIB Swiss 534

Institute of Bioinformatics), International Committee on Taxonomy of Viruses (ICTV) lists from 535 2022,⁸⁴ and a 2018 paper on Classification of Human Viruses.⁵³ We first assessed the ViralZone 536

- 537 list for viruses that were isolated in animals prior to any subsequent clusters of cases in humans,
- 538 excluding viruses for which only singleton human cases have been reported to focus on
- 539 pathogens of public health concern for potential outbreaks. We also used these lists to determine
- 540 the first recorded outbreak of any virus from each family with at least one virus known to infect
- 541 humans, either by conducting that search or systematically evaluating each virus known to infect humans in each family.
- 542
- 543

We approached the question of viral discovery once more by analyzing documented outbreaks in 544

humans. We subset Carlson et al.'s Disease Outbreak News database⁴⁷ to only include reports of 545

viral diseases and then analyzed the geographic and virological distribution of emerging disease 546

547 threats. We report frequency of DONs, noting that extended outbreaks are represented with more

548 frequent and recurring weekly reports. As a result, our visualization of DONs offers a proxy for

549 both the occurrence of a disease threat and the magnitude of it, which we chose over number of

550 cases or disability-adjusted life years to reflect national and international public health

551 institutions' concerns regarding disease preparedness and response rather than epidemiological

- 552 or economic statistics alone. We then referenced a WHO list of Public Health Emergency of 553 International Concern (PHEIC) declarations and performed a similar analysis of disease origins.

554 555 Our analysis of priority pathogens drew from the 4 lists created by international and national 556 bodies following the 2013-2016 Ebola epidemic, namely: WHO, NIAID (Category A), UKVN,

557 and CEPI. We compiled priority pathogens across these lists to focus on viral threats and then

558 conducted similar reviews to ascertain the circumstances in which each virus was first isolated.

559 The figure excludes smallpox, which only the NIAID lists prioritizes and on biosecurity grounds,

- because the WHO declared the virus eradicated in 1980 and the first of several vaccines against 560 561 the virus was developed in 1796.
- 562

We then used the virus families framework as described by Graham and Sullivan,⁸⁵ among 563 564 others, to evaluate the vaccine development landscape across virus families. We conducted a 565 literature review to determine the year in which a vaccine was first approved for use in humans, 566 primarily by a regulatory body — with the exception of rabies and smallpox, for which 567 widespread vaccination preceded any regulatory approval. We coupled our evaluation of vaccine 568 development with our analyses of when and how the first virus associated with each family was 569 isolated, irrespective of the specific virus' ability to infect humans. We focused on vaccines as 570 opposed to other medical countermeasures because of our focus on public health approaches to 571 preparedness over treatment in clinical settings, although we acknowledge the importance of 572 therapeutic and diagnostic development as other relevant aspects for future consideration. 573

574 For our filoviruses case study, we based our literature search on information from the United

575 States Centers for Disease Control and Prevention's (CDC) timeline of EVD and MVD

576 outbreaks over time. We used this timeline to then expand data collection to World Health 577 Organizational and sub-regional organizations' outbreak disease outbreak reports for additional 578 epidemiological information. These sources were used to find key publications through PubMed 579 and article citations to answer specific questions surrounding evidence for novel spillover and 580 general outbreak origins, the context within which an outbreak began, and the demographics 581 within which the virus spread. Case counts for each outbreak are based on laboratory-confirmed 582 and suspected cases, where possible. In ascertaining whether an outbreak was caused by a novel 583 spillover event, we used the following schematic: 1) True if both genomic and epidemiological 584 evidence supported a novel spillover event, given availability of genomic data; 2) Probable if 585 relatively conclusive genomic or epidemiological evidence but lacking evidence of the other form (provided both methods were available) or some other acknowledgement of uncertainty; 3) 586 587 Disputed/Possible with competing explanations and unresolved debates within the literature; 4) 588 *Unknown* if there was no evidence to whether a novel spillover event or existing circulating 589 infection could be identified as the source of the outbreak or if literature generally states that the 590 origins of a particular outbreak are unknown; 5) False if both genomic and epidemiological 591 evidence identified existing and circulating infections in humans as the outbreak source. We 592 conducted literature review for studies that found samples positive for *Ebolavirus* or 593 Marburgvirus by polymerase chain reaction or antigen test to characterize animal host discovery 594 over time, corroborated by GenBank searches for sequencing data. We did not include studies 595 that reported seropositivity for either filovirus because this analysis focuses on surveillance for 596 viruses to further understandings of potential pathogens rather than presence or absence of 597 known viruses that elucidate, for instance, traces of infection in animal hosts. These criteria 598 exclude several studies in which animal hosts are seropositive for a filovirus but none are 599 positive by a molecular test for the presence of virus. For similar reasons, we did not include the 600 many studies that describe efforts that failed to detect any sample that was positive for an 601 *Ebolavirus* or *Marburgvirus*. Finally, we searched PubMed for reviews of EVD and MVD 602 countermeasure development using the search terms "ebola," "marburg," and "filovirus" with 603 "countermeasures," "vaccine," "antibody," and "antiviral." These reviews guided the 604 construction of a set of relevant MCMs of interest, which then informed a further literature 605 search to ascertain the timeline of clinical development (e.g., not basic research) for these 606 countermeasures. The lack of any clinical trial beyond Phase I for MVD motivated further 607 characterization of preclinical research against marburgviruses. In parallel, the search terms "ebola," "marburg," and "filovirus" were used on ClinicalTrials.gov to determine the progression 608 609 of various countermeasures through clinical trials. Our dataset primarily includes the first 610 instance of a clinical trial in a particular phase for a particular vaccine or drug candidate and is 611 not comprehensive as to include all trials for comparing different dosage regimes or studying 612 efficacy in different populations, for example.

End Notes 613

- 614 Supplementary Information is available for this paper.
- 615 Author Contributions: M.L. and A.V.A. conceived of the study. A.V.A. developed and carried
- 616 out data collection and analyses. All authors contributed to writing the manuscript.
- 617 The authors thank Erin Mordecai for her comments on a later-stage version of this manuscript
- 618 and multiple participants at the Ecology and Evolution of Infectious Diseases Conference
- 619 (Stanford University, 2024) for comments on an earlier version of this work.
- 620 Competing Interests: A.V.A. was an intern for CEPI in 2023 and is a consultant for Centivax,
- 621 Inc. M.L. is on the Scientific Advisory Board for CEPI.
- 622 M.L. thanks the VK fund for CCDD, Open Philanthropy, and the DALHAP fund for supporting
- 623 this work. Correspondence and requests for materials should be addressed to M.L.

References

¹ Preston, E. C. About PREDICT | School of Veterinary Medicine. https://ohi.vetmed.ucdavis.edu/programsprojects/predict-project/about (2019).

² USAID Announces New \$125 Million Project To Detect Unknown Viruses With Pandemic Potential | Press Release. U.S. Agency for International Development https://www.usaid.gov/news-information/press-releases/oct-5-2021-usaid-announces-new-125-million-project-detect-unknown-viruses-pandemic-potential (2023).

³ Global Virome Project. Global Virome Project <u>https://www.globalviromeproject.org</u>.

⁴ Becker, D. J. et al. Dynamic and integrative approaches to understanding pathogen spillover. Philos Trans R Soc Lond B Biol Sci 374, 20190014 (2019).

⁵ WHO to identify pathogens that could cause future outbreaks and pandemics. https://www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-outbreaks-and-pandemics (2022).

⁶ Gostin, L. O. The pandemic treaty: a grand global social bargain. *Nature Medicine* (2024) doi:10.1038/d41591-024-00043-z.

⁷ Vora, N. M. *et al.* The Lancet–PPATS Commission on Prevention of Viral Spillover: reducing the risk of

pandemics through primary prevention. *The Lancet* **403**, 597–599 (2024). ⁸ Woolhouse, M., Scott, F., Hudson, Z., Howey, R. & Chase-Topping, M. Human viruses: discovery and emergence. Philos Trans R Soc Lond B Biol Sci 367, 2864–2871 (2012).

⁹ Ellwanger, J. H. & Chies, J. A. B. Zoonotic spillover: Understanding basic aspects for better prevention. *Genet* Mol Biol 44, e20200355.

¹⁰ Slingenbergh, J., Gilbert, M., Balogh De, K. & Wint, W. Ecological sources of zoonotic diseases: -EN- -FR- -ES-. Rev. Sci. Tech. OIE 23, 467-484 (2004).

¹¹ Carroll, D. *et al.* The Global Virome Project. *Science* **359**, 872–874 (2018).

¹² Carlson, C. J., Zipfel, C. M., Garnier, R. & Bansal, S. Global estimates of mammalian viral diversity accounting for host sharing. Nat Ecol Evol 3, 1070-1075 (2019).

¹³ Parker, C. \$75M pandemic warning system: UC Davis leads global effort to detect diseases moving from wildlife to people. UC Davis https://www.ucdavis.edu/news/75m-pandemic-warning-system-uc-davis-leads-global-effortdetect-diseases-moving-wildlife-people (2009).

¹⁴ PATHOGEN DETECTION & VIRAL DISCOVERY. *PREDICT Project* https://p2.predict.global/discovery. ¹⁵ Han, B. A., Kramer, A. M. & Drake, J. M. Global Patterns of Zoonotic Disease in Mammals. Trends Parasitol 32, 565-577 (2016).

¹⁶ Wille, M., Geoghegan, J. L. & Holmes, E. C. How accurately can we assess zoonotic risk? *PLOS Biology* 19, e3001135 (2021).

¹⁷ Mollentze, N. & Streicker, D. G. Viral zoonotic risk is homogenous among taxonomic orders of mammalian and avian reservoir hosts. Proc. Natl. Acad. Sci. U.S.A. 117, 9423-9430 (2020).

¹⁸ Cohen, L. E., Fagre, A. C., Chen, B., Carlson, C. J. & Becker, D. J. Coronavirus sampling and surveillance in bats from 1996–2019: a systematic review and meta-analysis. Nat Microbiol 8, 1176–1186 (2023).

¹⁹ Bernstein, A. S. *et al.* The costs and benefits of primary prevention of zoonotic pandemics. *Sci. Adv.* 8, eabl4183 (2022).

²⁰ Carlson, C. J. et al. Climate change increases cross-species viral transmission risk. Nature 607, 555–562 (2022).

²¹ Lemieux, A., Colby, G. A., Poulain, A. J. & Aris-Brosou, S. Viral spillover risk increases with climate change in High Arctic lake sediments. Proc. R. Soc. B. 289, 20221073 (2022).

²² Grange, Z. L. *et al.* Ranking the risk of animal-to-human spillover for newly discovered viruses. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2002324118 (2021).

²³ Amman, B. R. *et al.* A Recently Discovered Pathogenic Paramyxovirus, Sosuga Virus, is Present in Rousettus aegyptiacus Fruit Bats at Multiple Locations in Uganda. *J Wildl Dis* **51**, 774–779 (2015).

²⁴ Garland-Lewis, G., Whittier, C., Murray, S., Trufan, S. & Rabinowitz, P. M. Occupational Risks and Exposures Among Wildlife Health Professionals. *Ecohealth* **14**, 20–28 (2017).

²⁵ Willman, D. & Warrick, J. Research with exotic viruses risks a deadly outbreak, scientists warn. *Washington Post* https://www.washingtonpost.com/investigations/interactive/2023/virus-research-risk-outbreak/ (2024).

²⁶ Sandbrink, J., Ahuja, J., Swett, J., Koblentz, G. & Standley, C. Mitigating Biosecurity Challenges of Wildlife Virus Discovery. SSRN Scholarly Paper at https://doi.org/10.2139/ssrn.4035760 (2022).

²⁷ Willman, D. The US quietly terminates a controversial \$125m wildlife virus hunting programme amid safety fears. *BMJ* **382**, p2002 (2023).

²⁸ Holmes, E. C. COVID-19—lessons for zoonotic disease. *Science* **375**, 1114–1115 (2022).

²⁹ Holmes, E. C., Rambaut, A. & Andersen, K. G. Pandemics: spend on surveillance, not prediction. *Nature* **558**, 180–182 (2018).

³⁰ Carlson, C. J. From PREDICT to prevention, one pandemic later. *Lancet Microbe* **1**, e6–e7 (2020).

³¹ Grard, G. *et al.* A Novel Rhabdovirus Associated with Acute Hemorrhagic Fever in Central Africa. *PLOS Pathogens* **8**, e1002924 (2012).

³² Wolfe, N. D., Daszak, P., Kilpatrick, A. M. & Burke, D. S. Bushmeat Hunting, Deforestation, and Prediction of Zoonotic Disease - Volume 11, Number 12—December 2005 - Emerging Infectious Diseases journal - CDC. **11**, (2005).

³³ Carroll, D. *et al.* Preventing the next pandemic: the power of a global viral surveillance network. *BMJ* **372**, n485 (2021).

³⁴ Global Virome Project. *Global Virome Project* https://www.globalviromeproject.org (2021).

³⁵ Allen, T. *et al.* Global hotspots and correlates of emerging zoonotic diseases. *Nat Commun* **8**, 1124 (2017).

³⁶ Karesh, W. B. et al. Ecology of zoonoses: natural and unnatural histories. The Lancet **380**, 1936–1945 (2012).

³⁷ Flanagan, M. L. *et al.* Anticipating the Species Jump: Surveillance for Emerging Viral Threats. Copy at https://cobeylab.uchicago.edu/media/publication_files/a556992.pdf (2010).

³⁸ Gomes, B. M., Rebelo, C. B. & Alves de Sousa, L. Chapter 2 - Public health, surveillance systems and preventive medicine in an interconnected world. in *One Health* (eds. Prata, J. C., Ribeiro, A. I. & Rocha-Santos, T.) 33–71 (Academic Press, 2022). doi:10.1016/B978-0-12-822794-7.00006-X.

³⁹ Excler, J.-L., Saville, M., Berkley, S. & Kim, J. H. Vaccine development for emerging infectious diseases. *Nat Med* **27**, 591–600 (2021)

⁴⁰ Morse, S. S. et al. Prediction and prevention of the next pandemic zoonosis. The Lancet **380**, 1956–1965 (2012).

⁴¹ R&D Blueprint. World Health Organization https://www.who.int/teams/blueprint (2024).

⁴² Daszak, P. Lessons from COVID-19 to Help Prevent Future Pandemics. *CCDCW* **3**, 132–133 (2021).

⁴³ About Mpox | Mpox | Poxvirus | CDC. https://www.cdc.gov/poxvirus/mpox/about/index.html (2024).

⁴⁴ Zika virus. World Health Organization https://www.who.int/news-room/fact-sheets/detail/zika-virus (2022).

⁴⁵ Gerken, K. N. *et al.* Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021. *PLoS Negl Trop Dis* **16**, e0009852 (2022).

⁴⁶ Shchelkunova, G. A. & Shchelkunov, S. N. Smallpox, Monkeypox and Other Human Orthopoxvirus Infections. *Viruses* **15**, 103 (2022).

⁴⁷ Carlson, C. J. *et al.* The World Health Organization's Disease Outbreak News: A retrospective database. *PLOS Global Public Health* **3**, e0001083 (2023).

⁴⁸ Wilder-Smith, A. & Osman, S. Public health emergencies of international concern: a historic overview. *J Travel Med* **27**, taaa227 (2020).

⁴⁹ Priority diseases | CEPI. https://cepi.net/priority-diseases (2023).

⁵⁰ NIAID Biodefense Pathogens | NIAID: National Institute of Allergy and Infectious Diseases.

https://www.niaid.nih.gov/research/niaid-biodefense-pathogens (2024).

⁵¹ Noad, R. J. *et al.* UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. *Vaccine* **37**, 6241–6247 (2019).

⁵² Prioritizing diseases for research and development in emergency contexts. *World Health Organization* https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts (2024).

⁵³ Siegel, R. D. Classification of Human Viruses. *Principles and Practice of Pediatric Infectious Diseases* 1044-1048.e1 (2018) doi:10.1016/B978-0-323-40181-4.00201-2.

⁵⁴ CDC. Outbreak History. *Ebola* https://www.cdc.gov/ebola/outbreaks/index.html (2024).

⁵⁷ Fairhead, J., Leach, M. & Millimouno, D. Spillover or endemic? Reconsidering the origins of Ebola virus disease outbreaks by revisiting local accounts in light of new evidence from Guinea. *BMJ Global Health* 6, e005783 (2021).
 ⁵⁸ Goldstein, T. *et al.* Discovery of a new ebolavirus (Bombali virus) in molossid bats in Sierra Leone. *Nat*

Microbiol **3**, 1084–1089 (2018).

⁵⁹ Forbes, K. M. *et al.* Bombali Virus in Mops condylurus Bat, Kenya. *Emerg Infect Dis* **25**, 955–957 (2019). ⁶⁰ Bodmer, B. S. *et al.* In vivo characterization of the novel ebolavirus Bombali virus suggests a low pathogenic

potential for humans. *Emerg Microbes Infect* **12**, 2164216. ⁶¹ Kemenesi, G. *et al.* Isolation of infectious Lloviu virus from Schreiber's bats in Hungary. *Nat Commun* **13**, 1706 (2022).

⁶² He, B. *et al.* Isolation, characterization, and circulation sphere of a filovirus in fruit bats. *Proc. Natl. Acad. Sci.* U.S.A. **121**, e2313789121 (2024).

⁶³ Bodmer, B. S. *et al.* Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus. *Antiviral Res* **192**, 105120 (2021).

⁶⁴ Bentley, E. M. *et al.* Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay. *Trop Med Infect Dis* 6, 155 (2021).
 ⁶⁵ Plotkin, S. A., Mahmoud, A. A. F. & Farrar, J. Establishing a Global Vaccine-Development Fund. *N Engl J*

Med **373**, 297–300 (2015).

⁶⁶ Leendertz, S. A. J. Testing New Hypotheses Regarding Ebolavirus Reservoirs. *Viruses* 8, 30 (2016).
 ⁶⁷ Leroy, E. M. *et al.* Human asymptomatic Ebola infection and strong inflammatory response. *Lancet* 355, 2210–

2215 (2000).

⁶⁸ Halfmann, P. J. *et al.* Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study. *PLoS Negl Trop Dis* **13**, e0007654 (2019).

⁶⁹ Shaffer, K. C. L. *et al.* Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo. *PLoS Negl Trop Dis* **16**, e0010167 (2022).

⁷⁰ Kortepeter, M. G., Dierberg, K., Shenoy, E. S. & Cieslak, T. J. Marburg virus disease: A summary for clinicians. *Int J Infect Dis* **99**, 233–242 (2020).

⁷¹ Latinne, A. *et al.* One Health Surveillance Highlights Circulation of Viruses with Zoonotic Potential in Bats, Pigs, and Humans in Viet Nam. *Viruses* 15, 790 (2023).
 ⁷² Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after smallpox vaccination

⁷² Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci U S A* **107**, 16262–16267 (2010).
 ⁷³ Judson, S. D. & Munster, V. J. The Multiple Origins of Ebola Disease Outbreaks. *The Journal of Infectious*

⁷³ Judson, S. D. & Munster, V. J. The Multiple Origins of Ebola Disease Outbreaks. *The Journal of Infectious Diseases***228**, S465–S473 (2023).

⁷⁴ Plowright, R. K. *et al.* Ecological countermeasures to prevent pathogen spillover and subsequent pandemics. *Nat Commun* **15**, 2577 (2024).

⁷⁵ Osofsky, S. A., Lieberman, S., Walzer, C., Lee, H. L. & Neme, L. A. An immediate way to lower pandemic risk: (not) seizing the low-hanging fruit (bat). *The Lancet Planetary Health* **7**, e518–e526 (2023).

⁷⁶ Kamins, A. O. *et al.* Uncovering the fruit bat bushmeat commodity chain and the true extent of fruit bat hunting in Ghana, West Africa. *Biol Conserv* **144**, 3000–3008 (2011).

⁷⁷ Leroy, E. M. *et al.* Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007. *Vector-Borne and Zoonotic Diseases* **9**, 723–728 (2009).

⁷⁸ Jasanoff, S. Public Policy after Pandemic. *Boston Review* (2021).

⁷⁹ Akoi Boré, J. *et al.* Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea. *Nat Commun* **15**, 4171 (2024).

⁸⁰ Yinka-Ogunleye, A. *et al.* Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. *The Lancet Infectious Diseases* **19**, 872–879 (2019).

⁸¹ O'Toole, Á. *et al.* APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. *Science* **382**, 595–600 (2023).

⁸² Cohen, J. Africa intensifies battle against mpox as 'alarming' outbreaks continue. Preprint at https://doi.org/10.1126/science.zex54rl (2024).

⁵⁵ Bausch, D. G. *et al.* Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus. *N Engl J Med* **355**, 909–919 (2006).

⁵⁶ Marí Saéz, A. *et al.* Investigating the zoonotic origin of the West African Ebola epidemic. *EMBO Mol Med* **7**, 17–23 (2015).

⁸³ Swiss-Prot. Human viruses and associated pathologies. ViralZone / SIB Swiss Institute of Bioinformatics ⁸⁴ Master Species Lists | ICTV. https://ictv.global/msl.
 ⁸⁵ Graham, B. S. & Sullivan, N. J. Emerging viral diseases from a vaccinology perspective: preparing for the next

pandemic. Nat Immunol 19, 20-28 (2018).